NCT00475423View on ClinicalTrials.gov

A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.

PHASE2CompletedINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2011

Conditions
Idiopathic Thrombocytopenic Purpura
Interventions
DRUG

rituximab [MabThera/Rituxan]

1000mg iv on days 1 and 15

Trial Locations (12)

2139

Sydney

2145

Westmead

2250

Gosford

2747

Sydney

3052

Parkville

3144

Malvern

3168

Melbourne

3199

Frankston

4102

Woolloongabba

5011

Adelaide

5042

Adelaide

NSW 2031

Randwick

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00475423 - A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura. | Biotech Hunter | Biotech Hunter